Statins to improve cardiovascular outcomes in treated HIV infection

Current Opinion in Infectious Diseases

Volumn 29, Issue 1, 2016, Pages 1-9

  Longenecker, Chris T ^a,b   Eckard, Allison R ^c   McComsey, Grace A ^b,d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

HIV; Inflammation; Lipids; Statin

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN;

ANTIVIRAL THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; DRUG DOSE TITRATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INSULIN RESISTANCE; MONOCYTE; OBESITY; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; VASCULITIS; ARTERIAL WALL THICKNESS; CLINICAL PRACTICE; CORONARY DISEASE; EPIDEMIOLOGY; HIV INFECTIONS; HUMAN; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UNITED STATES;

ATORVASTATIN CALCIUM; CAROTID INTIMA-MEDIA THICKNESS; CORONARY DISEASE; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PRECISION MEDICINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROSUVASTATIN CALCIUM; TREATMENT OUTCOME; UNITED STATES;

EID: 84952720191     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000223     Document Type: Review

References (71)

1. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:1-9.
2. Sico JJ, Chang CC, So-Armah K, et al. HIV status and the risk of ischemic stroke among men. Neurology 2015; 84:1933-1940.
3. Boccara F, Lang S, Meuleman C, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol 2013; 61:511-523.
4. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
5. Monforte A, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS 2013; 27:407-415.
6. Longenecker CT, Triant VA. Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? Curr Opin HIV AIDS 2014; 9:54-62.
7. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
8. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373:1175-1182.
9. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278:313-321.
10. Mills EJ, O'Regan C, Eyawo O, et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J 2011; 32:1409-1415.
11. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S1-S45.
12. Cholesterol Treatment Trialists' (CTT) Collaborators. Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581-590.
13. Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297:1344-1353.
14. Rasmussen LD, Kronborg G, Larsen CS, et al. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One 2013; 8:e52828.
15. Overton ET, Kitch D, Benson CA, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013; 56:1471-1479.
16. Calza L, Manfredi R, Colangeli V, et al. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retroviruses 2013; 29:547-556.
17. Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004; 147:E18.
18. Hurlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing antiretroviral combination therapy: a randomised double blind crossover trial. Heart 2006; 92:110-112.
19. Mallon PW, Miller J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study. AIDS 2006; 20:1003-1010.
20. Lo J, Lu MT, Ihenachor EJ, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2015; 2:e52-e63.
21. Longenecker CT, Jiang Y, Debanne SM, et al. Rosuvastatin arrests progression of carotid intima-media thickness in treated HIV. In: 22nd Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA, USA; 2015.
22. Feinstein MJ, Achenbach CJ, Stone NJ, et al. A systematic review of the usefulness of statin therapy in HIV-infected patients. Am J Cardiol 2015; 115:1760-1766.
23. Calza L, Manfredi R, Colangeli V, et al. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008; 6:572-578.
24. Aslangul E, Assoumou L, Bittar R, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 2010; 24:77-83.
25. Silverberg MJ, Leyden W, Hurley L, et al. Response to newly prescribed lipidlowering therapy in patients with and without HIV infection. Ann Intern Med 2009; 150:301-313.
26. Johns KW, Bennett MT, Bondy GP. Are HIV positive patients resistant to statin therapy? Lipids Health Dis 2007; 6:27.
27. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011; 53:185-196.
28. Srinivasa S, Grinspoon SK. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. Eur J Endocrinol 2014; 170:R185-R202.
29. McComsey GA, Moser C, Currier JS, et al. Body Composition changes after initiation of raltegravir or protease inhibitors. In: Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA; 2015.
30. Brown TT, Smurzynski M, Wu K, et al. Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort. Antivir Ther 2009; 14:853-858.
31. Macallan DC, Baldwin C, Mandalia S, et al. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 2008; 9:254-268.
32. Calmy A, Bloch M, Wand H, et al. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med 2010; 11:493-501.
33. Erlandson KM, Jiang Y, Debanne SM, et al. Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults. AIDS 2015; 29:175-182.
34. Longenecker CT, Jiang Y, Yun CH, et al. Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy. Int J Cardiol 2013; 168:4039-4045.
35. Mira E, Manes S. Immunomodulatory and anti-inflammatory activities of statins. Endocr Metab Immune Disord Drug Targets 2009; 9:237-247.
36. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4:977-987.
37. Aslangul E, Fellahi S, Assoumou LK, et al. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS 2011; 25:1128-1131.
38. Calza L, Vanino E, Salvadori C, et al. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients. HIV Clin Trials 2014; 15:1-13.
39. Eckard AR, Jiang Y, Debanne SM, et al. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014; 209:1156-1164.
40. Fichtenbaum CJ, Evans SE, Aberg JA. High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. AIDS 2011; 25:2053.
41. De Wit S, Delforge M, Necsoi CV, et al. Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS 2011; 25:1332-1333.
42. Orfei L, Thompson A, Gao P, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-1544.
43. Investigators S, White HD, Held C, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014; 370:1702-1711.
44. Nakanjako D, Ssinabulya I, Nabatanzi R, et al. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Trop Med Int Health 2015; 20:380-390.
45. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr 2015; 68:396-404.
46. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis 2014; 58:588-595.
47. Overton ET, Sterrett S, Westfall AO, et al. Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients. AIDS 2014; 28:2627-2631.
48. Chronic Kidney Disease Prognosis C. Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
49. Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012; 156:570-581.
50. Longenecker CT, Hileman CO, Funderburg NT, et al. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis 2014; 59:1148-1156.
51. Dirajlal-Fargo S, Kinley B, Jiang Y, et al. Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial. AIDS 2015; 29:313-321.
52. Hale A, Longenecker C, Jiang Y, et al. HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4. AIDS 2015; 29:1643-1650.
53. Singh S, Willig JH, Mugavero MJ, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis 2011; 52:387-395.
54. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
55. Erlandson K, Jiang Y, Debanne S, et al. Rosuvastatin has minimal impact on bone, fat, and muscle among antiretroviral treated, HIV-infected adults: 96-week results of SATURN-HIV. In Press 2015.
56. Erlandson KM, Jiang Y, Debanne SM, et al. Rosuvastatin worsens insulin resistance in HIV-infected adults on antiretroviral therapy. Clin Infect Dis 2015; 61:1566-1572.
57. Erlandson K, Jiang Y, Debanne S, et al. minimal impact on bone, fat, and muscle among antiretroviral treated, HIV-infected adults: 96-week results of SATURN-HIV. In Press 2015.
58. Mateen FJ, Post WS, Sacktor N, et al. Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men. Neurology 2013; 81:2094-2102.
59. Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17:491-501.
60. Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr 2013; 62:149-163.
61. Justice AC, Tate JP, Freiberg MS, et al. Reply to Chow et al. Clin Infect Dis 2012; 55:751-752.
62. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S49-S73.
63. Mosepele M, Regan S, Meigs J, et al. Application of new ACC/AHA cholesterol guidelines to an HIV clinical care cohort. In: Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA; 2015.
64. Zanni MV, Fitch KV, Feldpausch M, et al. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical highrisk coronary plaque. AIDS 2014; 28:2061-2070.
65. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary. J Clin Lipidol 2014; 8:473-488.
66. Aberg JA, Fichtenbaum C, Gallant JE, et al. National lipid association recommendations for HIV infected persons. J Nat Lipid Associat 2015; in press.
67. Yu CY, Campbell SE, Sponseller CA, et al. Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers. Clin Drug Investig 2014; 34:475-482.
68. Malvestutto CD, Ma Q, Morse GD, et al. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr 2014; 67:390-396.
69. Custodio JM, Wang H, Hao J, et al. Pharmacokinetics of cobicistat boostedelvitegravir administered in combination with rosuvastatin. J Clin Pharmacol 2014; 54:649-656.
70. Kellick KA, Bottorff M, Toth PP. A clinician's guide to statin drug-drug interactions. J Clin Lipidol 2014; 8:S30-S46.
71. Freiberg MS, Leaf DA, Goulet JL, et al. The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication. J Gen Intern Med 2009; 24:334-340.